Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile

Journal of Nutrition, Health and Aging

Volumn 14, Issue 6, 2010, Pages 457-460

  Giovannini, Silvia ^a,b   Cesari, M ^b   Marzetti, E ^a   Leeuwenburgh, C ^a   Maggio, M ^c   Pahor, M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Angiotensin converting enzyme inhibitor; Insulin like growth factor 1; Insulin like growth factor binding protein 3; Older adults

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FOSINOPRIL; PLACEBO; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED; RISK FACTOR;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOSINOPRIL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RISK FACTORS;

EID: 77954655149     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-010-0036-7     Document Type: Article

References (20)

1. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386):782-788.
2. Yusuf S, Gerstein H, Hoogwerf B et al. Ramipril and the development of diabetes. JAMA 2001; 286(15):1882-1885.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3):145-153.
4. Maggio M, Ceda GP, Lauretani F et al. Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age (the InCHIANTI study). Am J Cardiol 2006; 97(10):1525-1529.
5. Onder G, Liperoti R, Russo A et al. Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: results from the IISIRENTE study. Eur J Clin Pharmacol 2007; 63(4):389-395. (Pubitemid 46399131)
6. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996; 97(11):2509-2516. (Pubitemid 26187338)
7. Colao A, Spiezia S, Di SC et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005; 28(5):440-448.
8. Martin RM, Gunnell D, Whitley E et al. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab 2008; 93(4):1331-1338.
9. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 1995; 9(3):361-367.
10. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997; 272(18):12181-12188.
11. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106(8):939-944.
12. Johnsen SP, Hundborg HH, Sorensen HT et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005; 90(11):5937-5941.
13. Corbalan R, Acevedo M, Godoy I, Jalil J, Campusano C, Klassen J. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. J Card Fail 1998; 4(2):115-119. (Pubitemid 28381149)
14. Diez J, Laviades C. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril. J Hypertens Suppl 1994; 12(4):S31-S36. (Pubitemid 24247675)
15. Cesari M, Kritchevsky SB, Baumgartner RN et al. Sarcopenia, obesity, and inflammation-results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr 2005; 82(2):428-434.
16. Cesari M, Kritchevsky SB, Atkinson HH et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J 2009; 157(2):334-338.
17. Anwar A, Gaspoz JM, Pampallona S et al. Effect of congestive heart failure on the insulin-like growth factor-1 system. Am J Cardiol 2002; 90(12):1402-1405.
18. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994; 45(2):598-604. (Pubitemid 24065099)
19. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab 2004; 89(1):114-120.
20. Kaplan RC, McGinn AP, Pollak MN et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 2007; 92(4):1319-1325.